…
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Cartesian Therapeutics Inc. (RNAC) is limited; the company describes itself as a developer of cell- and gene-based therapeutic candidates. Long-term growth drivers may include clinical development progress, regulatory approvals, platform scalability and successful commercialization, which could attract investors seeking exposure to the cell and gene therapy sector.
Material risks include early-stage clinical and regulatory uncertainty, high cash burn and financing needs, manufacturing complexity for cell therapies and intense competition in the biotech sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -139.50M | -77.14M | -238.71M | 34.77M | -9.72M |
| Net income | -130.30M | -77.42M | -219.71M | 35.38M | -25.69M |
| Selling general administrative | 31.47M | 30.13M | 40.58M | 23.86M | 20.94M |
| Gross profit | 2.80M | 38.91M | 24.45M | 108.74M | 85.08M |
| Reconciled depreciation | 2.96M | 1.15M | 0.84M | 1.29M | 1.25M |
| Ebit | -139.50M | -77.14M | -85.72M | 14.87M | -4.58M |
| Ebitda | -136.54M | -75.99M | -84.88M | 16.16M | -3.33M |
| Depreciation and amortization | 2.96M | 1.15M | 0.84M | 1.29M | 1.25M |
| Non operating income net other | - | - | - | 23.26M | -2.28M |
| Operating income | -86.70M | -43.90M | -86.42M | 14.54M | -4.60M |
| Other operating expenses | 89.50M | 82.81M | 112.42M | 96.24M | 89.67M |
| Interest expense | - | 0.00M | 2.83M | 3.03M | 2.84M |
| Tax provision | -9.19M | 0.29M | -19.00M | -0.61M | 15.97M |
| Interest income | 6.58M | 7.39M | - | 0.98M | 2.80M |
| Net interest income | 6.58M | 7.39M | -2.83M | -3.03M | -2.84M |
| Income tax expense | -9.19M | 0.29M | -19.00M | -0.61M | 15.97M |
| Total revenue | 2.80M | 38.91M | 26.00M | 110.78M | 85.08M |
| Total operating expenses | 89.50M | 82.81M | 112.42M | 96.24M | 89.67M |
| Cost of revenue | - | - | 1.55M | 2.04M | - |
| Total other income expense net | -52.79M | -33.24M | -149.46M | 23.26M | -2.28M |
| Net income from continuing ops | -130.30M | -77.42M | -219.71M | 35.38M | -25.69M |
| Net income applicable to common shares | - | - | - | 35.38M | -25.69M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 296.41M | 435.02M | 305.05M | 165.89M | 159.88M |
| Intangible assets | 93.90M | 150.60M | 150.60M | - | - |
| Other current assets | 3.02M | 3.14M | 4.97M | 3.78M | - |
| Total liab | 422.65M | 441.82M | 745.23M | 72.06M | 137.36M |
| Total stockholder equity | -126.24M | -6.80M | -440.18M | 93.83M | 22.52M |
| Other current liab | 9.50M | 19.84M | 60.58M | - | - |
| Common stock | 0.00M | 0.00M | 0.02M | - | - |
| Capital stock | 0.00M | 0.00M | 0.02M | 0.01M | 0.01M |
| Retained earnings | -822.37M | -692.07M | -614.65M | -394.94M | -430.32M |
| Good will | 48.16M | 48.16M | 48.16M | - | - |
| Cash | 125.14M | 212.61M | 76.91M | 106.44M | 114.06M |
| Total current liabilities | 14.94M | 22.98M | 68.21M | 25.08M | 72.25M |
| Current deferred revenue | - | - | 2.31M | - | - |
| Net debt | -112.46M | -198.63M | -65.96M | - | - |
| Short term debt | 4.15M | 2.85M | 2.17M | - | - |
| Short long term debt | - | - | - | 8.48M | 5.96M |
| Short long term debt total | 12.68M | 13.98M | 10.96M | - | - |
| Other stockholder equity | 700.71M | 689.89M | -117.80M | - | - |
| Total current assets | 129.28M | 216.63M | 90.73M | 148.14M | 144.44M |
| Long term investments | 0.00M | 2.00M | 2.00M | 2.00M | 2.00M |
| Short term investments | - | - | 0.00M | 28.16M | 14.00M |
| Net receivables | 1.11M | 0.87M | 8.85M | 6.60M | 9.91M |
| Long term debt | - | - | - | 17.79M | 19.67M |
| Accounts payable | 1.29M | 0.29M | 3.15M | 0.32M | 0.22M |
| Accumulated other comprehensive income | -4.58M | -4.62M | -4.60M | - | - |
| Non currrent assets other | 99.45M | 2.19M | 1.38M | 1.34M | 1.47M |
| Non current assets total | 167.13M | 218.40M | 214.32M | 17.75M | 15.44M |
| Capital lease obligations | 12.68M | 13.98M | 10.96M | 11.66M | 9.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -8.74M | 34.61M | -13.80M | -16.05M |
| Change to liabilities | - | - | - | 1.70M | 1.44M |
| Total cashflows from investing activities | -5.45M | -8.74M | - | -15.00M | -17.14M |
| Net borrowings | - | 0.00M | - | - | - |
| Total cash from financing activities | -8.05M | 168.43M | -13.14M | 39.22M | 52.90M |
| Change to operating activities | - | - | - | - | -0.39M |
| Net income | -130.30M | -77.42M | -219.71M | 35.38M | -25.69M |
| Change in cash | -87.41M | 135.99M | -29.75M | -7.40M | -24.63M |
| Begin period cash flow | 214.28M | 78.29M | 108.04M | 115.44M | 140.06M |
| End period cash flow | 126.87M | 214.28M | 78.29M | 108.04M | 115.44M |
| Total cash from operating activities | -73.94M | -23.67M | -51.16M | -31.63M | -60.38M |
| Issuance of capital stock | 0.00M | 164.44M | 20.25M | 38.98M | 51.96M |
| Depreciation | 2.96M | 1.15M | 0.84M | 1.29M | 1.25M |
| Other cashflows from investing activities | - | 0.35M | - | -13.80M | -16.05M |
| Change to inventory | - | - | -3.85M | 0.92M | 0.21M |
| Change to account receivables | -0.24M | 7.98M | 0.73M | 3.32M | -2.69M |
| Sale purchase of stock | - | 0.00M | -6.17M | 0.19M | 0.16M |
| Other cashflows from financing activities | -7.75M | 43.99M | 34.61M | -0.11M | -17.14M |
| Change to netincome | - | - | - | -8.88M | 11.07M |
| Capital expenditures | 5.45M | 9.09M | 0.21M | 1.20M | 1.08M |
| Change receivables | - | - | - | 3.32M | -2.69M |
| Cash flows other operating | - | - | - | -64.06M | -45.83M |
| Exchange rate changes | - | - | - | - | -0.00M |
| Cash and cash equivalents changes | - | - | - | -7.42M | -24.63M |
| Change in working capital | -8.06M | -5.79M | 4.97M | -60.38M | -48.19M |
| Stock based compensation | 10.52M | 6.58M | 22.52M | 11.19M | 7.72M |
| Other non cash items | 60.14M | 51.52M | 159.21M | 2.29M | 2.13M |
| Free cash flow | -79.39M | -32.77M | -51.37M | -32.83M | -61.47M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics Inc. |
-0.01 0.08% |
6.35 | - | 25.06 | 161.62 | 31.26 | 107.99 | 1.77 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
7495 New Horizon Way, Frederick, MD, United States, 21703
301 348 8698
75
| Name | Title | Year Born |
|---|---|---|
| Dr. Carsten Brunn Ph.D. | President, CEO & Director | 1972 |
| Mr. Blaine T. Davis | Chief Financial Officer | 1975 |
| Dr. Metin Kurtoglu M.D., Ph.D. | Chief Operating Officer | 1979 |
| Yi Zhang Ph.D. | Senior Director of Technology | NA |
| Dr. Chris Jewell Ph.D. | Chief Scientific Officer | 1982 |
| Mr. Matthew Bartholomae J.D. | General Counsel & Secretary | NA |
| Dr. Milos Miljkovic M.D., Ph.D. | Chief Medical Officer | 1984 |
| Dr. Carsten Brunn Ph.D. | President, CEO & Chairman of the Board | 1971 |
| Mr. Blaine T. Davis | Chief Financial Officer | 1974 |
| Dr. Emily English Ph.D. | Chief Operating Officer | 1980 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.